EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin

Samy Belkaïd, Emmanuel Ribereau-Gayon, Sylvie Chabaud, Julien Anriot, Thibald Chalas, Aude Fléchon, Helen Boyle, Armelle Vinceneux, Frédéric Bérard, Benoît You, Gilles Freyer, Sophie Darnis und 2 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115427 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Samy Belkaïd und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologie, Centre Léon Bérard, Lyon, France; Dermatologie, Hôpital Lyon Sud, Hospices Civils de Lyon, Oullins-Pierre-Bénite, France; Université Cl…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Drug Eruptions, Immunoconjugates, Urologic Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalDrug EruptionsImmunoconjugatesUrologic NeoplasmsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedAged, 80 and overProgression-Free SurvivalAdult

Stichwörter der Autor:innen

Adverse EffectsAntibody-Drug ConjugatesEnfortumab VedotinRashSkin DiseasesSurvival RateTreatment OutcomeUrothelial Carcinoma

Substanzen

enfortumab vedotinAntibodies, MonoclonalImmunoconjugates

Autor:innen und Institutionen

  • Dermatologie, Centre Léon Bérard, Lyon, France; Dermatologie, Hôpital Lyon Sud, Hospices Civils de Lyon, Oullins-Pierre-Bénite, France; Université Claude Bernard Lyon 1, Villeurbanne, France. Electronic address: samy.be…
  • Dermatologie, Hôpital Lyon Sud, Hospices Civils de Lyon, Oullins-Pierre-Bénite, France; Université Claude Bernard Lyon 1, Villeurbanne, France.
  • Direction de la Recherche Clinique et de l'Innovation, Centre Léon Bérard, Lyon, France.
  • Dermatologie, Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon 1, Villeurbanne, France.
  • Oncologie médicale, Centre Léon Bérard, Lyon, France.
  • Dermatologie, Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon 1, Villeurbanne, France; Immunologie clinique et allergologie, Hôpital Lyon Sud, Hospices Civils de Lyon, Oullins-Pierre-Bénite, France.

Zitieren

APA

Belkaïd, S., Ribereau-Gayon, E., Chabaud, S., Anriot, J., Chalas, T., Fléchon, A., Boyle, H., Vinceneux, A., Bérard, F., You, B., Freyer, G., Darnis, S., Tartas, S., & Amini-Adle, M. (2025). Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115427

Vancouver

Belkaïd S, Ribereau-Gayon E, Chabaud S, Anriot J, Chalas T, Fléchon A, et al. Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115427

BibTeX
@article{Belkad2025,
  author = {Belkaïd, Samy and Ribereau-Gayon, Emmanuel and Chabaud, Sylvie and Anriot, Julien and Chalas, Thibald and Fléchon, Aude and Boyle, Helen and Vinceneux, Armelle and Bérard, Frédéric and You, Benoît and Freyer, Gilles and Darnis, Sophie and Tartas, Sophie and Amini-Adle, Mona},
  title = {Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115427}
}
Kostenlos starten →